A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

I8F-MC-GPGU -

This is a study of tirzepatide in very overweight participants. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat.

Trial Summary

Age Range
18 - 60 years
Conditions the trial is for
Obesity
What the trial is testing?
Tirzepatide, Placebo
Could I receive a Placebo?
Yes
Enrollment Goal
55
Trial Dates
Jul 9, 2020 - May 26, 2022
How long will I be in the trial?
The study will last 28 weeks and will include about 21 visits to the study center.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must be considered to be very overweight

  • Participants must have stable body weight in the past 1 month

  • Participants must agree to commit to and undergo study procedures as explained by clinic study staff

Participants Must Not:

  • Participants must not have undergone weight loss surgery (e.g. stomach stapling, lapbanding)

  • Participants must not have been diagnosed as having diabetes

  • Participants must not have used or intend to use weight loss drugs

  • Participants must not have donated blood in the past month

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.